We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




FDA Clears Specialty Applications for Radiology Platform

By MedImaging International staff writers
Posted on 03 Jul 2017
Print article
Image: The Longitudinal Brain Imaging (LoBI) is the newest Intellispace 9.0 portal clinical application approved US distribution (Photo courtesy of Philips Healthcare).
Image: The Longitudinal Brain Imaging (LoBI) is the newest Intellispace 9.0 portal clinical application approved US distribution (Photo courtesy of Philips Healthcare).
The US FDA has provided 510(k) clearance for new oncology, neurology and cardiology advanced applications for image comparison and analysis, and evaluation treatments and therapy response assessment.

The latest release of the clinical informatics platform now includes new advanced clinical applications for multi-modality tumor tracking, optimized lung-nodule assessment, and longitudinal brain imaging.

The new applications are for the Royal Philips (Amsterdam, the Netherlands) IntelliSpace Portal 9.0 portal, and are now available for marketing in the US. The most recent innovation cleared by the FDA was the Longitudinal Brain Imaging (LoBI) application that can be used to analyze brain images for tracking neurodegenerative disorders including stroke, Multiple Sclerosis (MS), and Alzheimer's disease. New oncology functionality includes qEASL, part of the Multi-Modality Tumor Tracking application, for enhanced tumor volume measurements using Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans. The new Lung Nodule Assessment tool provides information about lung nodules from a single CT study, and can also track them across multiple studies.

The IntelliSpace Portal 9.0 portal already offers more than 70 radiology, cardiology, oncology, and neurology applications, and provides a comprehensive overview of a patient’s health. The new applications can enable clinicians to evaluate patients faster, across modalities, and to track therapy response over time.

Leiden University Medical Center professor of neuroradiology, Mark van Buchem, said, "Analytics applications optimized for clinical decision support and longitudinal and quantified patient tracking are becoming increasingly important to radiologists. They can help visualize and quantify very subtle manifestations of disease and differences over time that may not be seen with the naked eye. IntelliSpace Portal 9.0 integrates into our existing workflow and adds greatly to our patient care."

New
Ultrasonic Pocket Doppler
SD1
Diagnostic Ultrasound System
MS1700C
Ultra-Flat DR Detector
meX+1717SCC
LED-Based X-Ray Viewer
Dixion X-View

Print article

Channels

Ultrasound

view channel
Image: Experimental design of the study (Photo courtesy of Tatiana Estifeeva et al./Biomaterials Advances)

New Contrast Agent for Ultrasound Imaging Ensures Affordable and Safer Medical Diagnostics

Ultrasound imaging is an affordable and non-invasive diagnostic method that uses widely available equipment. However, its results are often not highly accurate, and the image quality is heavily dependent... Read more

Nuclear Medicine

view channel
Image: CD45-PET is a robust, non-invasive tool for imaging inflammation (Photo courtesy of 123RF)

Breakthrough Method Detects Inflammation in Body Using PET Imaging

Inflammation is an immune response that helps protect the body against disease. However, when inflammation becomes chronic and excessive, it can lead to various long-term conditions, including cardiovascular... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.